Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Invivyd, Inc.

Get SEC filing alerts via email and in your feed for Invivyd, Inc.

IVVD

Invivyd, Inc.

About Invivyd, Inc.

Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies for viral infectious diseases, starting with COVID-19. Its core products include PEMGARDA for COVID-19 pre-exposure prophylaxis and VYD2311, a next-generation antibody candidate. The company leverages antibody discovery, engineering, and surveillance to create long-lasting, broadly neutralizing therapies, partnering with contract manufacturers and research organizations to support development, manufacturing, and commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Invivyd, Inc.

1
1
Invivyd, Inc. Invivyd Reports $41.4 Million Net Loss in Q1 2026, Revenue Increases to $13.7 Million

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Invivyd, Inc. Invivyd Reports $52.5 Million Net Loss and $53.4 Million Revenue for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Invivyd, Inc. Invivyd Reports 41% Revenue Growth to $13.1 Million, Net Loss Improves in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Invivyd, Inc. Invivyd Reports $11.8M Product Revenue and $14.7M Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Invivyd, Inc. Invivyd Reports $11.3 Million Product Revenue in Q1 2025, Faces Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Invivyd, Inc. Invivyd Reports $169.9 Million Net Loss for 2024, Highlights PEMGARDA Sales

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Invivyd, Inc. Invivyd Reports $9.3M in Product Revenue, Substantial Losses in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments